Gottlieb outlines plans to modernize cancer drug development, review

By Erin McCallister | Jun 2, 2018 | 4:28 PM GMT

At the American Society of Clinical Oncology (ASCO) meeting on Saturday, FDA Commissioner Scott Gottlieb highlighted steps the agency is taking to speed cancer drug development and review, including a pilot review program for supplemental efficacy applications, new guidance to relax enrollment criteria in